Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine During Breast Cancer Surgery for Prevention of Postoperative Depression
ChiCTR2200063001Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) and breast cancer (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: PHQ-9 depression score. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)breast cancer
Beyond the preview
Go deeper on ChiCTR2200063001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063001.